The latest announcement is out from Living Cell Technologies ( (AU:1AI) ).
Algorae Pharmaceuticals has made significant advancements in its AI drug discovery platform, AlgoraeOS, identifying 24 novel oncology-focused drug targets and progressing the development of AlgoraeOS Version 2.0 with enhanced AI capabilities. The company is also advancing its therapeutic pipeline with promising pre-clinical results for its dementia and cardiovascular drug candidates, AI-116 and AI-168, respectively. The appointment of a new Chief Commercial Officer and strategic guidance from the Scientific Advisory Board are expected to strengthen Algorae’s market execution and commercialization efforts.
More about Living Cell Technologies
Algorae Pharmaceuticals is an AI-enabled pharmaceutical development company focused on discovering and developing novel treatments for unmet medical needs. The company’s proprietary AI platform, AlgoraeOS, utilizes machine learning and deep neural networks to identify synergistic drug combinations with the potential to transform patient outcomes. Algorae collaborates with leading research institutions and pharmaceutical partners to accelerate the translation of AI-predicted therapies into clinical practice.
Technical Sentiment Signal: Strong Buy
Current Market Cap: $5.38M
For detailed information about 1AI stock, go to TipRanks’ Stock Analysis page.